These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

181 related items for PubMed ID: 19539516

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Estimated medication costs of primary TNFα antagonist failure in patients with rheumatoid arthritis.
    Rose E, Lequerré T, Pouplin S, Daragon A, Le Loët X, Vittecoq O.
    Joint Bone Spine; 2012 Jul; 79(4):421-2. PubMed ID: 22512937
    [No Abstract] [Full Text] [Related]

  • 24. [Autoimmune aspects of treatment with TNF-alpha inhibitors].
    Kolarz B, Targońska-Stepniak B, Darmochwał-Kolarz D, Majdan M.
    Postepy Hig Med Dosw (Online); 2007 Aug 28; 61():478-84. PubMed ID: 17786135
    [Abstract] [Full Text] [Related]

  • 25. Clinical application and evaluation of anti-TNF-alpha agents for the treatment of rheumatoid arthritis.
    Jin J, Chang Y, Wei W.
    Acta Pharmacol Sin; 2010 Sep 28; 31(9):1133-40. PubMed ID: 20711219
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. TNF inhibitors: a new age in rheumatoid arthritis treatment.
    Anderson DL.
    Am J Nurs; 2004 Feb 28; 104(2):60-8; quiz 68-9. PubMed ID: 14767382
    [No Abstract] [Full Text] [Related]

  • 28. Differences in annual medication costs and rates of dosage increase between tumor necrosis factor-antagonist therapies for rheumatoid arthritis in a managed care population.
    Ollendorf DA, Klingman D, Hazard E, Ray S.
    Clin Ther; 2009 Apr 28; 31(4):825-35. PubMed ID: 19446156
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Retention rates of adalimumab, etanercept and infliximab as first and second-line biotherapy in patients with rheumatoid arthritis in daily practice.
    Frazier-Mironer A, Dougados M, Mariette X, Cantagrel A, Deschamps V, Flipo RM, Logeart I, Schaeverbeke T, Sibilia J, Le Loët X, Combe B.
    Joint Bone Spine; 2014 Jul 28; 81(4):352-9. PubMed ID: 24721422
    [Abstract] [Full Text] [Related]

  • 34. Survival of TNF-alpha antagonists in rheumatoid arthritis: a long-term study.
    Markatseli TE, Alamanos Y, Saougou I, Voulgari PV, Drosos AA.
    Clin Exp Rheumatol; 2012 Jul 28; 30(1):31-8. PubMed ID: 22153557
    [Abstract] [Full Text] [Related]

  • 35. TNFalpha antagonist continuation rates in 442 patients with inflammatory joint disease.
    Brocq O, Roux CH, Albert C, Breuil V, Aknouche N, Ruitord S, Mousnier A, Euller-Ziegler L.
    Joint Bone Spine; 2007 Mar 28; 74(2):148-54. PubMed ID: 17368068
    [Abstract] [Full Text] [Related]

  • 36. Adalimumab in rheumatoid arthritis after failed infliximab and/or etanercept therapy: experience with 18 patients.
    Brocq O, Albert C, Roux C, Gerard D, Breuil V, Ziegler LE.
    Joint Bone Spine; 2004 Nov 28; 71(6):601-3. PubMed ID: 15589452
    [No Abstract] [Full Text] [Related]

  • 37. The yin and yang of tumor necrosis factor inhibitors.
    Calabrese L.
    Cleve Clin J Med; 2006 Mar 28; 73(3):251-6. PubMed ID: 16548447
    [Abstract] [Full Text] [Related]

  • 38. Cost effectiveness of tumour necrosis factor-alpha inhibitors as first-line agents in rheumatoid arthritis.
    Spalding JR, Hay J.
    Pharmacoeconomics; 2006 Mar 28; 24(12):1221-32. PubMed ID: 17129076
    [Abstract] [Full Text] [Related]

  • 39. [Treatment of rheumatic diseases: current status and future prospective. Topics: III. Biological drugs; 1. TNF inhibitors].
    Amano K.
    Nihon Naika Gakkai Zasshi; 2011 Oct 10; 100(10):2966-71. PubMed ID: 22175139
    [No Abstract] [Full Text] [Related]

  • 40. Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial.
    Smolen JS, Kay J, Doyle MK, Landewé R, Matteson EL, Wollenhaupt J, Gaylis N, Murphy FT, Neal JS, Zhou Y, Visvanathan S, Hsia EC, Rahman MU, GO-AFTER study investigators.
    Lancet; 2009 Jul 18; 374(9685):210-21. PubMed ID: 19560810
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.